First patient dosed in the pivotal phase III study OCEAN with Ygalo® (melflufen)
Stockholm - June 14, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the first patient has been dosed in the pivotal phase III study OCEAN. The study is targeting Late-Stage Relapsed Refractory (RRMM) patients with Multiple Myeloma.The study is designed as a head-to-head comparative study where the result will show whether Ygalo® is more effective, just as effective, or less effective than the current standard of care treatment option pomalidomide for late-stage RRMM patients."We are of the firm belief that Ygalo® will help late-stage multiple myeloma patients both in